- Home
- NUVL vs SWX Comparison
NUVL vs SWX Comparison
Compare NUVL & SWX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- SWX
- Stock Information
- Founded
- NUVL 2017
- SWX 1931
- Country
- NUVL United States
- SWX United States
- Employees
- NUVL N/A
- SWX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- SWX Oil & Gas Production
- Sector
- NUVL Health Care
- SWX Utilities
- Exchange
- NUVL Nasdaq
- SWX Nasdaq
- Market Cap
- NUVL 5.5B
- SWX 5.6B
- IPO Year
- NUVL 2021
- SWX N/A
- Fundamental
- Price
- NUVL $79.49
- SWX $76.87
- Analyst Decision
- NUVL Strong Buy
- SWX Hold
- Analyst Count
- NUVL 11
- SWX 4
- Target Price
- NUVL $112.36
- SWX $74.00
- AVG Volume (30 Days)
- NUVL 420.4K
- SWX 353.4K
- Earning Date
- NUVL 03-04-2025
- SWX 02-26-2025
- Dividend Yield
- NUVL N/A
- SWX 3.23%
- EPS Growth
- NUVL N/A
- SWX N/A
- EPS
- NUVL N/A
- SWX 2.50
- Revenue
- NUVL N/A
- SWX $5,209,839,000.00
- Revenue This Year
- NUVL N/A
- SWX N/A
- Revenue Next Year
- NUVL N/A
- SWX $2.06
- P/E Ratio
- NUVL N/A
- SWX $30.80
- Revenue Growth
- NUVL N/A
- SWX N/A
- 52 Week Low
- NUVL $61.80
- SWX $61.13
- 52 Week High
- NUVL $113.51
- SWX $80.29
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- SWX 58.38
- Support Level
- NUVL $77.84
- SWX $76.66
- Resistance Level
- NUVL $85.21
- SWX $78.07
- Average True Range (ATR)
- NUVL 3.78
- SWX 1.31
- MACD
- NUVL -0.46
- SWX -0.00
- Stochastic Oscillator
- NUVL 12.08
- SWX 61.10
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About SWX Southwest Gas Holdings Inc. (DE)
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution and Utility Infrastructure Services units. The first of these encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. The natural gas distribution division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers. The Utility Infrastructure Services segment generates the other half of the company's total revenue from the underground piping contractor services that its subsidiary, Centuri Construction Group, provides.